Vaccines against lyme disease: What happened and what lessons can we learn?

Gregory A. Poland

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

This article reviews events that led to the withdrawal of the only vaccine to prevent Lyme disease licensed in the United States. The primary issues that led to the vaccine's withdrawal appear to be a combination of vaccine safety concerns, sparked by a molecular mimicry hypothesis that suggested that the vaccine antigen, outer surface protein A, serves as an autoantigen and hence was arthritogenic; concerns raised by anti-vaccine groups regarding vaccine safety; vaccine cost; a difficult vaccination schedule and the potential need for boosters; class action lawsuits; uncertainty regarding risk of disease; and low public demand. This article reviews lessons learned from these events and proposes that future candidate Lyme disease vaccines are unlikely to be developed, tested, and used within the United States in the near future, thus leaving at-risk populations unprotected.

Original languageEnglish (US)
Pages (from-to)S253-S258
JournalClinical Infectious Diseases
Volume52
Issue numberSUPPL. 3
DOIs
StatePublished - Feb 1 2011

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Vaccines against lyme disease: What happened and what lessons can we learn?'. Together they form a unique fingerprint.

Cite this